Navigation Links
Nasdaq Grants VirtualScopics' Request for Continued Listing
Date:10/9/2008

Extension until February 3, 2009 to meet continued listing criteria

ROCHESTER, N.Y., Oct. 9 /PRNewswire-FirstCall/ -- VirtualScopics, Inc. (Nasdaq: VSCP) today announced that the Nasdaq Hearings Panel has granted the Company's request to remain listed on the Nasdaq Capital Market and has allowed the Company until February 3, 2009 to regain compliance with the minimum bid price. The Panel's decision represents the full extent of the Panel's authority to grant an exception pursuant to Marketplace Rule 4802(b). The Company's hearing before the Panel was held on September 18, 2008. The decision of the Panel to grant the Company's request for continued listing is subject to the condition that the Company must have evidenced a closing bid price of $1.00 or more for a minimum of ten consecutive trading days by February 3, 2009. In the event the Company does not comply with these conditions, its common stock may be suspended from The Nasdaq Capital Market.

"We are very pleased with the Panel's decision to grant us additional time to regain compliance," stated Ms. Molly Henderson, Chief Business and Financial Officer of VirtualScopics, Inc. She further added, "The extension allows the market time to react as we continue to deliver on our stated 2008 financial objectives. We believe the company is well positioned to capitalize on the opportunities within the industry and are confident that we have built a strong foundation for a profitable business."

As previously announced, the Company requested a hearing before the Nasdaq Hearings Panel following its receipt on August 7, 2008 of a Staff Deficiency Letter from the Nasdaq Stock Market notifying it that it no longer meets The Nasdaq Stock Market's minimum bid price requirement for continued listing set forth in Marketplace Rule 4450(a)(5). The Company has received stockholder approval and is prepared to effectuate a reverse stock split in the event that it has not met the minimum bid price by year end.

About VirtualScopics, Inc.

VirtualScopics, Inc. is a leading provider of imaging solutions to accelerate drug and medical device development. VirtualScopics has developed a robust software platform for analysis and modeling of both structural and functional medical images. In combination with VirtualScopics' industry-leading experience and expertise in advanced imaging biomarker measurement, this platform provides a uniquely clear window into the biological activity of drugs and devices in clinical trial patients, allowing sponsors to make better decisions faster. For more information about VirtualScopics, visit http://www.virtualscopics.com.

Forward-Looking Statements

The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure and new customer contract signings and awards in 2008 and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations. Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at http://www.sec.gov.

CONTACT: Company Contact:

Molly Henderson

Chief Business and Financial Officer

500 Linden Oaks

Rochester, New York 14625

(585)249.6231


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. deCODE Receives Nasdaq Deficiency Notice Relating to Market Value
2. Monogram Receives NASDAQ Notification
3. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
4. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
5. Telik Announces Receipt of Nasdaq Notice
6. Vermillion Announces Receipt of NASDAQ Panel Decision
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
8. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
9. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
10. CTI Receives NASDAQ Letter
11. China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... 31, 2016 BioRap Technologies Ltd ... Biomedical Research at the Technion - Israel Institute of Technology, ... with Pfizer Inc. (NYSE: PFE ) that aims ... treatment options for a number of chronic autoimmune diseases. ... by Prof. Nathan Karin and his research team, ...
(Date:5/31/2016)... MB (PRWEB) , ... May 31, 2016 , ... ... develops and markets molecular imaging systems, today announced that their compact PET scanner ... (Magnetic Resonance Imaging) has been selected by the University of Arizona (UA). , ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Weeks after hosting ... in Phoenix, Dr. Michael Fitzmaurice, hand surgeon and founder of the Fitzmaurice Hand Institute, ... The Wrist MRI machine is a state-of-the-art technology and only 1 of about 3 ...
(Date:5/27/2016)... Jersey and READING, ... -- Indegene ( http://www.indegene.com ), ... marketingorientierten Lösungen für die Life-Science-Branche, Pharmaunternehmen und ... bekannter weltweiter Anbieter von innovativen wissenschaftlichen Support-Services ... des Starts von IntraScience heute den Ausbau ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):